StockNews.AI
IMMX
StockNews.AI
4 hrs

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

1. Nancy T. Chang joins Immix Biopharma Board, enhancing leadership. 2. Dr. Chang has a successful history, leading XOLAIR® to $5 billion in sales. 3. Immix's NXC-201 has met key endpoints in trials, showing promise. 4. Regulatory designations for NXC-201 signal potential market entry. 5. Further data on NXC-201's trials remains crucial for future success.

6m saved
Insight
Article

FAQ

Why Bullish?

The addition of an experienced leader may enhance investor confidence. Historical instances show successful executives can drive stock prices positively.

How important is it?

Dr. Chang’s expertise can significantly alter stakeholder perception and market position. Short-term visibility into NXC-201's success will impact trading decisions.

Why Short Term?

Immediate effects can be seen due to leadership change and trial results. As NXC-201 progresses, short-term investor reactions are likely.

Related Companies

GENNLLYRHHBY
 – Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far –  Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Company”, “We” or “Us”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that Nancy T. Chang, former Tanox, Inc. CEO and proven biotechnology leader, has joined the Immix Biopharma Board of Directors concurrent with her investment as founding member of Goose Capital. At Tanox, Dr. Chang and her team invented and developed FDA-approved XOLAIR® (omalizumab) for severe asthma, TROGARZO® (ibalizumab-uiyk) for HIV, and EBGLYSS® (lebrikizumab-lbkz) for dermatitis, collectively generating drug sales exceeding 5 billion dollars so far. Tanox, Inc. was acquired by Genentech/Roche for $919 million. EBGLYSS® is commercialized by Eli Lilly and Co. About Immix Biopharma, Inc.Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that filters out non-specific activation. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NEXICART-2 primary endpoint was met at interim results presented at ASCO 2025. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com. Forward Looking StatementsThis press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, the potential benefits of our product candidate CAR-T NXC-201 and the timing and results related clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1/2 clinical trials for CAR-T NXC-201 will not be favorably consistent with the data readouts to date, (ii) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (iii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iv) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (v) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (vi) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2025 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. ContactsMike MoyerLifeSci Advisorsmmoyer@lifesciadvisors.com Company Contactirteam@immixbio.com

Related News